Search Results

• • 26 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Targeted therapies for renal cell carcinoma: review of adverse event management strategies

  Authors:Tim Eisen, Cora N. Sternberg, Caroline Robert, Peter Mulders, Lynda Pyle, Stephan Zbinden, et al.From:Journal of the National Cancer Institute (Vol. 104, Issue 2) Peer-Reviewed

  Jan. 18, 2012 Author abstract, Rep...

   Citation Only

• Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy

  Authors:Cora N. Sternberg, Fabio Calabro, Giorgio Pizzocaro, Luca Marini, Sylvia Schnetzer, and Avishay SellaFrom:Cancer (Vol. 92, Issue 12) Peer-Reviewed

  Dec. 15, 2001 Article

   Citation Only

• Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.

  Authors:Thomas Powles, Se Hoon Park, Eric Voog, Claudia Caserta, Begona P. Valderrama, Howard Gurney, et al.From:The New England Journal of Medicine (Vol. 383, Issue 13) Peer-Reviewed

  Sept. 24, 202059 words Report

   Citation Only

• Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder

  Authors:Cora N. Sternberg, Maria G. Arena, Federico Calabresi, Piero De Carli, Andrea Platania, Massimo Zeuli, et al.From:Cancer (Vol. 72, Issue 6) Peer-Reviewed

  Sept. 15, 1993244 words Article

   Abstract Only

• Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials

  Authors:Michael T. Schweizer, Peng Huang, Michael W. Kattan, Adam S. Kibel, Ronald de Wit, Cora N. Sternberg, et al.From:Cancer (Vol. 119, Issue 20) Peer-Reviewed

  Oct. 15, 2013 Report

   Citation Only

• Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy

  Authors:Susan Halabi, Chen-Yen Lin, Eric J. Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel Petrylak, et al.From:Journal of the National Cancer Institute (Vol. 105, Issue 22) Peer-Reviewed

  Nov. 20, 2013280 words Author abstract, Rep...

   Abstract Only

• Is there a role for presurgical therapy for renal cell carcinoma?

  Authors:Fabio CalabroA[sup.2] and Cora N SternbergFrom:Expert Review of Anticancer Therapy (Vol. 10, Issue 6) Peer-Reviewed

  June 20104,630 words Report 1530LAuthor(s): Fabio Calabròò 1 , Cora N Sternberg [[dagger]â ] 2 Keywords : bevacizumab; biomarkers of resistance; neoadjuvant therapy; presurgical therapy; radical nephrectomy; renal cell carcinoma; sorafenib;...

• Pazopanib versus sunitinib in metastatic renal-cell carcinoma

  Authors:Toni K. Choueiri, Lini N. Pandite, Rocco Crescenzo, Michelle D. Hackshaw, Lauren McCann, Keith Deen, et al.From:The New England Journal of Medicine (Vol. 369, Issue 8) Peer-Reviewed

  Aug. 22, 201345 words Report

   Citation Only

• Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

  Authors:Ronald de Wit, Johann de Bono, Cora N. Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wulfing, et al.From:The New England Journal of Medicine (Vol. 381, Issue 26) Peer-Reviewed

  Dec. 26, 201951 words Report

   Citation Only

• Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma

  Authors:Fabio Calabro, Vito Lorusso, Gerardo Rosati, Luigi Manzione, Luca Frassineti, Teodoro Sava, et al.From:Cancer (Vol. 115, Issue 12) Peer-Reviewed

  June 15, 2009 Clinical report

   Citation Only

• Abiraterone and increased survival in metastatic prostrate cancer

  Authors:Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, et al.From:The New England Journal of Medicine (Vol. 364, Issue 21) Peer-Reviewed

  May 26, 201145 words Clinical report

   Citation Only

• Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study

  Authors:David J. Vaughn, Sandy Srinivas, Walter M. Stadler, Roberto Pili, Daniel Petrylak, Cora N. Sternberg, et al.From:Cancer (Vol. 115, Issue 18) Peer-Reviewed

  Sept. 15, 2009 Clinical report

   Citation Only

• Can patient selection for bladder preservation be based on response to chemotherapy?

  Authors:Cora N. Sternberg, Vito Pansadoro, Fabio Calabro, Sylvia Schnetzer, Diana Giannarelli, Paolo Emiliozzi, et al.From:Cancer (Vol. 97, Issue 7) Peer-Reviewed

  Apr. 1, 2003 Article

   Citation Only

• Transurethral resection of the prostate and metastatic prostate cancer

  Authors:Vito Pansadoro, Cora N. Sternberg, Francesco DePaula, Alberto Florio, Diana Giannarelli, and Giorgio ArcangeliFrom:Cancer (Vol. 68, Issue 9) Peer-Reviewed

  Nov. 1, 1991275 words Article

   Abstract Only

• Castration-resistant prostate cancer: current and emerging treatment strategies

  Authors:Giuseppe Di Lorenzo, Carlo Buonerba, Riccardo Autorino, Sabino De Placido, and Cora N. SternbergFrom:Drugs (Vol. 70, Issue 8) Peer-Reviewed

  May 15, 201010,070 words Report 1790LUntil very recently, docetaxel was the only approved agent in castration-resistant prostate cancer (CRPC) and other effective therapeutic options are urgently needed. In recent years, several new agents with promising...

• Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.

  Authors:Christopher Sweeney, Sergio Bracarda, Cora N Sternberg, Kim N Chi, David Olmos, Shahneen Sandhu, et al.From:The Lancet (Vol. 398, Issue 10295) Peer-Reviewed

  July 10, 2021949 words Article

   Abstract Only

• Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer

  Authors:Lothar Thomas, Herbert Leyh, Michael Marberger, Emilio Bombardieri, Pierfrancesco Bassi, Francesco Pagano, et al.From:Clinical Chemistry (Vol. 45, Issue 4) Peer-Reviewed

  Apr. 19994,253 words Article 1460L

   Citation Only

• Satraplatin for the therapy of castration-resistant prostate cancer

  Authors:Guru Sonpavde and Cora N SternbergFrom:Future Oncology (Vol. 5, Issue 7) Peer-Reviewed

  Sept. 20095,961 words Drug overview Author(s): Guru Sonpavde 1 , Cora N Sternberg [[dagger]] 2 Keywords: Keywords castration-resistant prostate cancer; oral chemotherapy; platinum; satraplatin; tolerability Docetaxel-based chemotherapy...

• Enzalutamide in Men with Nonmetastatic, castration-Resistant Prostate Cancer

  Authors:Maha Hussain, Karim Fizazi, Fred Saad, Per Rathenborg, Neal Shore, Ubirajara Ferreira, et al.From:The New England Journal of Medicine (Vol. 378, Issue 26) Peer-Reviewed

  June 28, 201850 words Report

   Citation Only

• Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.

  Authors:Cora N. Sternberg, Karim Fizazi, Fred Saad, Neal D. Shore, Ugo De Giorgi, David F. Penson, et al.From:The New England Journal of Medicine (Vol. 382, Issue 23) Peer-Reviewed

  June 4, 202055 words Report

   Citation Only